{"id":2732,"date":"2011-12-01T17:29:55","date_gmt":"2011-12-01T16:29:55","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii"},"modified":"2020-04-07T16:11:27","modified_gmt":"2020-04-07T14:11:27","slug":"complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/","title":{"rendered":"Complications post-op\u00e9ratoires dans le cadre d&#8217;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#8217;un essai prospectif de phase II"},"content":{"rendered":"<p><span>J Clin Oncol 29: 2011 (suppl. abstr 569) &#8211; 2011 ASCO Annual Meeting<\/span><\/p>\n<p><span>R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, \u00a0 J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, D. Pau, P. Viens, R.J. Salmon<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>J Clin Oncol 29: 2011 (suppl. abstr 569) &#8211; 2011 ASCO Annual Meeting R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, \u00a0 J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, D. Pau, P. Viens, R.J. Salmon<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[63],"class_list":["post-2732","post","type-post","status-publish","format-standard","hentry","category-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Complications post-op\u00e9ratoires dans le cadre d&#039;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#039;un essai prospectif de phase II - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Complications post-op\u00e9ratoires dans le cadre d&#039;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#039;un essai prospectif de phase II - RCTs\" \/>\n<meta property=\"og:description\" content=\"J Clin Oncol 29: 2011 (suppl. abstr 569) &#8211; 2011 ASCO Annual Meeting R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, \u00a0 J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, D. Pau, P. Viens, R.J. Salmon\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2011-12-01T16:29:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:11:27+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Complications post-op\u00e9ratoires dans le cadre d&#8217;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#8217;un essai prospectif de phase II\",\"datePublished\":\"2011-12-01T16:29:55+00:00\",\"dateModified\":\"2020-04-07T14:11:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/\"},\"wordCount\":68,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/\",\"name\":\"Complications post-op\u00e9ratoires dans le cadre d'un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d'un essai prospectif de phase II - RCTs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2011-12-01T16:29:55+00:00\",\"dateModified\":\"2020-04-07T14:11:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Complications post-op\u00e9ratoires dans le cadre d&#8217;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#8217;un essai prospectif de phase II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Complications post-op\u00e9ratoires dans le cadre d'un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d'un essai prospectif de phase II - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/","og_locale":"en_US","og_type":"article","og_title":"Complications post-op\u00e9ratoires dans le cadre d'un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d'un essai prospectif de phase II - RCTs","og_description":"J Clin Oncol 29: 2011 (suppl. abstr 569) &#8211; 2011 ASCO Annual Meeting R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, \u00a0 J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, D. Pau, P. Viens, R.J. Salmon","og_url":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/","og_site_name":"RCTs","article_published_time":"2011-12-01T16:29:55+00:00","article_modified_time":"2020-04-07T14:11:27+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/#article","isPartOf":{"@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/"},"author":{"name":"Didier Not","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Complications post-op\u00e9ratoires dans le cadre d&#8217;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#8217;un essai prospectif de phase II","datePublished":"2011-12-01T16:29:55+00:00","dateModified":"2020-04-07T14:11:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/"},"wordCount":68,"commentCount":0,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"articleSection":["Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/","url":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/","name":"Complications post-op\u00e9ratoires dans le cadre d'un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d'un essai prospectif de phase II - RCTs","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"datePublished":"2011-12-01T16:29:55+00:00","dateModified":"2020-04-07T14:11:27+00:00","breadcrumb":{"@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rcts.fr\/en\/complications-post-operatoires-dans-le-cadre-dun-traitement-neoadjuvant-incluant-le-bevacizumab-dans-le-cancer-du-sein-inflammatoire-csi-her2-positif-resultats-dun-essai-prospectif-de-phase-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Complications post-op\u00e9ratoires dans le cadre d&#8217;un traitement n\u00e9oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif : r\u00e9sultats d&#8217;un essai prospectif de phase II"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2732"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2732\/revisions"}],"predecessor-version":[{"id":2734,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2732\/revisions\/2734"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}